Galbriela Kit
Product Images NDC 70700-306

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Galbriela (NDC 70700-306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Relevant Studies Of Risk Of Breast Cancer With Combined Oral Contraceptives (Image 01)

A forest plot showing effect estimates comparing ever combined oral contraceptive (COC) use versus never use, and current COC use versus never use, across multiple studies. The plot includes odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals, illustrating the association between COC use and outcomes with effect estimates on the x-axis.*

FDA Label Image

Ethinyl Estradiol Structural Formula (Image 02)

Chemical structure of ethinyl estradiol, an active ingredient in GALBRIELA, showing its molecular framework with a characteristic ethynyl group and hydroxyl substitutions as part of the steroidal core.*

FDA Label Image

Norethindrone Structural Formula (Image 03)

Chemical structure diagram depicting the molecular structure of an active ingredient related to the product GALBRIELA, containing norethindrone and ethinyl estradiol and ferrous fumarate.*

FDA Label Image

Fda-approved Pateint Labeling (Image 04)

An illustration diagram showing methods of pregnancy prevention ranked by effectiveness. The diagram uses a vertical arrow indicating fewer pregnancies at the top and more pregnancies at the bottom, with specific methods listed in boxes including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Fda-approved Patient Labeling (Image 05)

GALBRIELA kit label for 28 tablets containing norethindrone and ethinyl estradiol 0.8 mg/0.025 mg and ferrous fumarate. The label includes a weekly calendar for dosing with circular tablet positions spanning Sunday through Saturday over four weeks. It displays storage instructions at 20° to 25°C and highlights that it is a prescription drug by Xiromed, LLC with NDC 70700-306-84.*

FDA Label Image

Norethindrone And Ethinyl Estradiol Tablets (chewable) And Ferrous Fumarate Tablets (chewable) Carton (Image 06)

GALBRIELA 0.8 mg/0.025 mg kit packaging label for human prescription drug containing norethindrone, ethinyl estradiol tablets (chewable), and ferrous fumarate tablets (chewable). The label indicates 3 pouches per kit, each pouch containing 28 tablets total. Manufactured by Xiromed, LLC. The label includes dosage strengths, tablet description, and a warning that the product does not protect against HIV or other sexually transmitted diseases.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.